TheraRadar
← Back
Data updated: Jun 28, 2026

BWXT ITG

Generics

BWXT ITG is a generic drug manufacturer focused on Infectious Disease.

2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

BWXT ITG's Key Drugs

BWXT ITG's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

BWXT ITG's Recent FDA Approvals

New NDA/BLA approvals for BWXT ITG over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

BWXT ITG's Therapeutic Areas

BWXT ITG's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 100%
1 drugs

BWXT ITG's Top Competitors

BWXT ITG's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

BWXT ITG Pipeline Snapshot

Active clinical trials for BWXT ITG across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling